IdCLTI R2B-project leads the way for a new era in cardiovascular diagnostics. The project prepares to identify chronic limb-threatening ischemia (CLTI) earlier and more accurately than currently is possible. The project launched on August 1st and is led by a Senior Researcher Petra Korpisalo-Pirinen (PRECISE research group). The project is part of Business Finland's Health 360 programme.
Background
Ischemic cardiovascular diseases (iCVDs) remain the leading cause of death worldwide. Among iCVDs, CLTI is the single most expensive disease to treat. Its early stages mainly go unnoticed and thereby treatments at the time of diagnosis have lost their best effect. The project idea is based on new understanding of capillary dysfunction in CLTI that shows promise for patient identification prior to severe arterial and tissue complications.
Goal
The aim of the project is to investigate the possibilities of commercialising a new, automated, non-invasive imaging technology for population-level screening of CLTI and iCVDs.
Impact
The project technology is designed for stopping CLTI and iCVD progression before arterial blood vessels are even affected. Earlier treatment referral makes it possible to still prevent severe tissue complications. The solution has broad international commercial potential and positive impacts on patient well-being and the use of healthcare resources.
Funding source
Business Finland Research to Business
Main funder
Business Finland
Contact persons
petra.korpisalo-pirinen [at] tuni.fi